Lino Gabriel Moreira, Ishibashi Felipe Shoji, Conrado George Alessandro Maranhão, Bresani-Salvi Cristiane Campello, Galvão Pauliana Valéria Machado
Serra Talhada Campus, University of Pernambuco, Serra Talhada, Brazil.
Oswaldo Cruz Foundation, Recife, Brazil.
BMC Pregnancy Childbirth. 2025 Jul 12;25(1):760. doi: 10.1186/s12884-025-07872-x.
This meta-analysis and systematic review aimed to review the health outcomes of offspring following dipyrone use during pregnancy.
A systematic literature search was conducted in MEDLINE, Embase, and the Cochrane Library to identify clinical trials or observational studies investigating women who used dipyrone during pregnancy (up to 16 August 2024). The data was analyzed using odds ratios (ORs) with inverse variance and Bayesian random effects models.
Six case-control studies and four prospective cohort studies met the inclusion criteria. No association was found with birth defects (OR 1.27, 95% CI 0.83–1.77; = 39.94%; 3 cohorts and 1 case-control), major anomalies (OR 1.06, 95% CI 0.47–2.37; = 14.35%; 2 cohorts), infant leukemia (OR 1.25, 95% CI 0.86–2.22; = 72.82%; 2 case-controls), gestational loss (OR 0.80, 95% CI 0.57–1.13; 3 cohorts), prematurity (OR 0.99, 95% CI 0.80–1.21; = 0%; 3 cohorts), low birth weight, constriction of the ductus arteriosus, or renal and cardiac disorders. However, all analyses were of low or very low certainty.
No association was found between maternal use of dipyrone in the investigated outcomes, although these conclusions are limited by the quality of the included studies, sample size, and overall evidence. Further research with a better assessment of exposure is required to exclude risk.
The online version contains supplementary material available at 10.1186/s12884-025-07872-x.
本荟萃分析和系统评价旨在回顾孕期使用安乃近后子代的健康结局。
在MEDLINE、Embase和Cochrane图书馆进行系统文献检索，以识别调查孕期使用安乃近的女性的临床试验或观察性研究（截至2024年8月16日）。使用具有逆方差的比值比（OR）和贝叶斯随机效应模型分析数据。
六项病例对照研究和四项前瞻性队列研究符合纳入标准。未发现与出生缺陷（OR 1.27，95%CI 0.83–1.77； = 39.94%；3个队列和1项病例对照研究）、主要畸形（OR 1.06，95%CI 0.47–2.37； = 14.35%；2个队列）、婴儿白血病（OR 1.25，95%CI 0.86–2.22； = 72.82%；2项病例对照研究）、妊娠丢失（OR 0.80，95%CI 0.57–1.13；3个队列）、早产（OR 0.99，95%CI 0.80–1.21； = 0%；3个队列）、低出生体重、动脉导管狭窄或肾脏和心脏疾病有关。然而，所有分析的确定性都很低或非常低。
在所调查的结局中，未发现母亲使用安乃近之间存在关联，尽管这些结论受到纳入研究的质量、样本量和总体证据的限制。需要进行更好地评估暴露情况的进一步研究以排除风险。
在线版本包含可在10.1186/s12884-025-07872-x获取的补充材料。
